Results 41 to 50 of 158 matches
Category 6 - PATHOLOGY SERVICES
73336 - Additional Information
A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.
Fee: $230.95 Benefit: 75% = $173.25 85% = $196.35
Category 6 - PATHOLOGY SERVICES
73337 - Additional Information
A test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, if the test is:
(a) to determine if requirements relating to epidermal growth factor receptor (EGFR) gene status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled; and
(b) not associated with a service to which item 73437 or 73438 applies
Fee: $397.35 Benefit: 75% = $298.05 85% = $337.75
(See para PN.7.15 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73338 - Additional Information
A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if:
(a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if:
- the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or
- a clinically-relevant RAS variant is detected;
and, in cases where no RAS variant is detected
(b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.
Fee: $362.60 Benefit: 75% = $271.95 85% = $308.25
(See para PN.0.26 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73339 - Additional Information
Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who manages the treatment of the patient.
One test. (Item is subject to rule 25)
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
(See para PN.0.23 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73340 - Additional Information
Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient.
One test. (Item is subject to rule 25)
Fee: $200.00 Benefit: 75% = $150.00 85% = $170.00
(See para PN.0.23 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73341 - Additional Information
Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of anaplastic lymphoma kinase (ALK) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score > 0, and with documented absence of activating mutations of the epidermal growth factor receptor (EGFR) gene, requested by a specialist or consultant physician, if the test is:
(a) to determine if requirements relating to ALK gene rearrangement status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled; and
(b) not associated with a service to which item 73437 or 73439 applies
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
(See para PN.7.15 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73342 - Additional Information
An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.
Fee: $315.40 Benefit: 75% = $236.55 85% = $268.10
(See para PN.1.2 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73343 - Additional Information
Detection of 17p chromosomal deletions by fluorescence in situ hybridisation or genome wide micro‑array, in a patient with chronic lymphocytic leukaemia or small lymphocytic lymphoma, on a peripheral blood, bone marrow or lymph node sample, requested by a specialist or consultant physician
For any particular patient:
(a) at initial diagnosis; or
(b) at disease relapse; or
(c) on disease progression;
but only where initiation of, or change in, therapy is anticipated
Fee: $589.90 Benefit: 75% = $442.45 85% = $501.45
Category 6 - PATHOLOGY SERVICES
73344 - Additional Information
Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of ROS proto-oncogene 1 (ROS1) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+; and with documented absence of both activating mutations of the epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) immunoreactivity by IHC, requested by a specialist or consultant physician, if the test is:
(a) to determine if requirements relating to ROS1 gene arrangement status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled: and
(b) not associated with a service to which item 73437 or 73439 applies
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
(See para PN.1.2, PN.7.15 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73345 - Additional Information
Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of investigating, making or excluding a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73347, 73348, or 73349 applies.
The patient must have clinical or laboratory findings suggesting there is a high probability suggestive of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder.
Fee: $500.00 Benefit: 75% = $375.00 85% = $425.00
(See para PN.7.3, PN.7.16 of explanatory notes to this Category)
Results 41 to 50 of 158 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change